Liver Cirrhosis
Conditions
Interventions
Exosome Treatment Group:Menstrual Blood Mesenchymal Stem Cell derived exosomes
Sponsors
Shulan (Hangzhou)Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) 18-75 years old (including boundary value); (2) Meet the diagnostic criteria for liver cirrhosis in the Guidelines for Diagnosis and Treatment of Liver Cirrhosis (2019 edition); (3) Hepatic cirrhosis portal vein pressure was measured by HVPG=10mmHg; (4) The subjects' heart, lungs, kidneys and other important organs function normally; (5) Child-Pugh score is grade A to B (5-9 points) and MELD score =20 points; (6) Prothrombin activity greater than 40% (prothrombin time less than 18 seconds), platelets greater than 30×10^9 /L; (7) The subject (or guardian) has signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) People who are highly allergic or have a history of severe allergy or allergy to known ingredients of the drug or have a history of iodine allergy; (2) The Child-Pugh score of cirrhosis was grade C (10-15 points), the MELD score was > 20 points, and the total bilirubin was > 3mg/dL; (3) Gastrointestinal hemorrhage, spontaneous peritonitis, hepatic encephalopathy, hepatorenal syndrome and acute infection; (4) Patients treated with portal vein thrombosis and TIPS (5) Malignant tumors of the liver or other organs; (6) dysfunction of the heart, lungs, kidneys and other important organs of the whole body; (7) with AIDS, syphilis, tuberculosis and other infectious diseases; (8) The patient was enrolled in another trial study 10 days before the trial or will be enrolled in another trial study within 90 days after the trial begins; (9) Pregnant and lactating women and men who have a birth plan within one year; (10) Combined with severe bacterial infection; (11) Have participated in stem cell clinical research; (12) is receiving other arterial dosing or therapy that may affect the dosing operator in this trial; (13) drug addiction or alcohol abuse; (14) splenectomy patients; (15) Other researchers did not consider the subjects suitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic Venous Pressure Gradient(HVPG);Liver biopsy;Adverse events/serious adverse events rate;Laboratory examination;Vital sign;Physical examination;electrocardiogram; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function;Complication rate;MELD Score?Child Score?FIB-4 Score and SF-36 Score;Liver Stiffness Measure, CAP, Spleen Stiffness;Imaging index; | — |
Countries
China
Contacts
Public ContactHuadong Yan
Shulan (Hangzhou)Hospital Affiliated to Zhejiang Shuren University Shulan International
Outcome results
None listed